1
|
Jafari F, Safaei AM, Hosseini L, Asadian S, Kamangar TM, Zadehbagheri F, Rezaeian N. The role of cardiac magnetic resonance imaging in the detection and monitoring of cardiotoxicity in patients with breast cancer after treatment: a comprehensive review. Heart Fail Rev 2020; 26:679-697. [PMID: 33029698 DOI: 10.1007/s10741-020-10028-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 09/15/2020] [Indexed: 01/04/2023]
Abstract
The use of chemotherapy medicines for breast cancer (BC) has been associated with an increased risk of cardiotoxicity. In recent years, there have been growing interests regarding the application of cardiovascular magnetic resonance (CMR) imaging, a safe and noninvasive modality, with the potential to identify subtle morphological and functional changes in the myocardium. In this investigation, we aimed to review the performance of various CMR methods in diagnosing cardiotoxicity in BC, induced by chemotherapy or radiotherapy. For this purpose, we reviewed the literature available in PubMed, MEDLINE, Cochrane, Google Scholar, and Scopus databases. Our literature review showed that CMR is a valuable modality for identifying and predicting subclinical cardiotoxicity induced by chemotherapy. The novel T1, T2, and extracellular volume mapping techniques may provide critical information about cardiotoxicity, in addition to other CMR features such as functional and structural changes. However, further research is needed to verify the exact role of these methods in identifying cardiotoxicity and patient management. Since multiple studies have reported the improvement of left ventricular performance following the termination of chemotherapy regimens, CMR remains an essential imaging tool for the prediction of cardiotoxicity and, consequently, decreases the mortality rate of BC due to heart failure.
Collapse
Affiliation(s)
- Fatemeh Jafari
- Department of Radiation Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.,Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Afsane Maddah Safaei
- Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Leila Hosseini
- North Khorasan University of Medical Sciences, Bojnurd, Iran
| | - Sanaz Asadian
- Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Tara Molanaie Kamangar
- Radiation Oncology Research Center (RORC), Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran
| | | | - Nahid Rezaeian
- Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.
| |
Collapse
|
2
|
Valero M, Courand PY, Gilbert T, Bonnin N, Bonnefoy M, Lantelme P, Falandry C. Geriatric oncologists should be aware of cardio-oncology: Impact of age and gender on 5-FU-mediated TakoTsubo cardiomyopathy. J Geriatr Oncol 2020; 11:1337-1339. [PMID: 32280034 DOI: 10.1016/j.jgo.2020.03.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2020] [Accepted: 03/26/2020] [Indexed: 10/24/2022]
Affiliation(s)
- Marie Valero
- Geriatric Unit, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France
| | - Pierre-Yves Courand
- Cardiology Department, European Society of Hypertension Excellence Center, Croix-Rousse Hospital and Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France; Lyon University, CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Thomas Gilbert
- Geriatric Unit, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France; Health Services and Performance Research (HESPER EA7425), Lyon, France
| | - Nathalie Bonnin
- Oncology Unit, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France
| | - Marc Bonnefoy
- Geriatric Unit, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France; Lyon University, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Charles Mérieux Medical School, Oullins, France
| | - Pierre Lantelme
- Cardiology Department, European Society of Hypertension Excellence Center, Croix-Rousse Hospital and Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France; Lyon University, CREATIS, CNRS UMR5220, INSERM U1044, INSA-Lyon, Université Claude Bernard Lyon 1, Lyon, France
| | - Claire Falandry
- Geriatric Unit, Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France; Lyon University, CarMeN Laboratory, Inserm U1060, INRA U1397, Université Claude Bernard Lyon 1, INSA Lyon, Charles Mérieux Medical School, Oullins, France.
| |
Collapse
|